{
    "ticker": "IVDA",
    "name": "InVivo Therapeutics Holdings Corp.",
    "description": "InVivo Therapeutics Holdings Corp. is a pioneering biotechnology company focused on developing innovative solutions for the treatment of spinal cord injuries. Founded in 2010 and headquartered in Cambridge, Massachusetts, InVivo is committed to advancing the field of neurotrauma through its proprietary technologies. The company's lead product candidate is a biopolymer scaffold designed to promote nerve regeneration and improve functional outcomes for patients with spinal cord injuries. InVivo's mission is to transform the treatment landscape for spinal cord injuries by providing effective therapies that leverage the body's natural healing processes. The company has made significant strides in clinical research, demonstrating promising results in early-phase studies. In addition to its flagship product, InVivo is actively exploring other therapeutic avenues within the realm of neuroregeneration. The company's commitment to innovation is reflected in its collaborative partnerships with leading research institutions and healthcare providers, as well as its focus on advancing scientific understanding of spinal cord injury mechanisms. As the demand for effective therapies in this field grows, InVivo is poised to play a crucial role in improving the lives of individuals affected by spinal cord injuries, driving forward its vision of restoring mobility and function.",
    "industry": [
        "Biotechnology",
        "Medical Devices"
    ],
    "headquarters": "Cambridge, Massachusetts, USA",
    "founded": "2010",
    "website": "https://www.invivotherapeutics.com",
    "ceo": "Frank Reynolds",
    "social_media": {
        "twitter": "https://twitter.com/invivotherapeutics",
        "linkedin": "https://www.linkedin.com/company/invivo-therapeutics/"
    },
    "investor_relations": "https://ir.invivotherapeutics.com",
    "key_executives": [
        {
            "name": "Frank Reynolds",
            "position": "CEO"
        },
        {
            "name": "Lynn Allen",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "Biopolymer Scaffold"
            ]
        }
    ],
    "seo": {
        "meta_title": "InVivo Therapeutics | Innovative Solutions for Spinal Cord Injury",
        "meta_description": "Discover InVivo Therapeutics Holdings Corp., a biotechnology pioneer dedicated to developing innovative therapies for spinal cord injuries. Learn about our technologies and mission.",
        "keywords": [
            "InVivo Therapeutics",
            "Spinal Cord Injury",
            "Biotechnology",
            "Neuroregeneration",
            "Medical Devices"
        ]
    },
    "faq": [
        {
            "question": "What does InVivo Therapeutics specialize in?",
            "answer": "InVivo Therapeutics specializes in developing therapies for spinal cord injuries using innovative biopolymer scaffold technology."
        },
        {
            "question": "Who is the CEO of InVivo Therapeutics?",
            "answer": "Frank Reynolds is the CEO of InVivo Therapeutics Holdings Corp."
        },
        {
            "question": "Where is InVivo Therapeutics headquartered?",
            "answer": "InVivo Therapeutics is headquartered in Cambridge, Massachusetts, USA."
        },
        {
            "question": "What is InVivo's lead product?",
            "answer": "InVivo's lead product is a biopolymer scaffold designed to promote nerve regeneration in patients with spinal cord injuries."
        },
        {
            "question": "When was InVivo Therapeutics founded?",
            "answer": "InVivo Therapeutics was founded in 2010."
        }
    ],
    "competitors": [
        "AXGN",
        "SPNC",
        "NVTA"
    ],
    "related_stocks": [
        "VRTX",
        "BMY",
        "AMGN",
        "GILD"
    ]
}